Due to the intricate pathophysiology of AD, which involves tau, Aβ, neuroinflammation, and vascular dysfunction, single-target mAbs are limited, necessitating bispecific antibodies that target multiple pathways simultaneously [108]. The gene discussed is MAPT; the disease is Alzheimer disease.